Last reviewed · How we verify
NCT07415577: Swisskera
The Use of Cultured (Dermal) Epithelial Autografts in Severely Burned Patients
trial testing Standard of Care (SOC) in Burn Degree Second in 236 participants. Not yet recruiting.
31 December 2029
Quick facts
| Lead sponsor | University Children's Hospital, Zurich |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 236 |
| Start date | 1 December 2026 |
| Primary completion | 31 December 2029 |
| Estimated completion | 31 December 2030 |
| Sites | 3 locations across Switzerland |
Drugs / interventions tested
- Standard of Care (SOC) — full drug profile →
Conditions studied
- Burn Degree Second — all drugs for Burn Degree Second →
- Burn Degree Third — all drugs for Burn Degree Third →
- Skin Transplantation — all drugs for Skin Transplantation →
- Full Thickness Skin Defects — all drugs for Full Thickness Skin Defects →
Sponsor
University Children's Hospital, Zurich
Who can join
Eligibility, any sex, with Burn Degree Second or Burn Degree Third. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Swisskera project is a multicenter follow-up study at the three Swiss burn centers evaluating long-term outcomes after burn wound coverage with lab-grown epithelial grafts, specifically cultured epithelial autograft (CEA) and, where applicable, cultured dermal-epidermal autograft (CDEA). Patients who received CEA/CDEA between 1985 and 2023 will be invited for a study visit , using available clinical records and standardized long-term scar and skin assessments. Long-term skin quality will be evaluated by comparing the previously transplanted area with a matched healthy skin reference site using non-invasive measurements (e.g., thickness, transepidermal water loss, hydration, elasticity, and color). Optional small punch biopsies may be obtained from transplanted areas (under local anesthesia or during clinically indicated anesthesia) for histological and immunohistochemical characterization of scar tissue remodeling, including collagen and elastin architecture, vascularization, nerve fiber ingrowth, inflammatory cell patterns, and melanocyte distribution.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07415577
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Standard of Care (SOC)
Trials testing the same drug.
- NCT07329946 — Immuno-inflammatory Response of Erdosteine in COPD · NA · not yet recruiting
- NCT07461961 — CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock · Phase 2 · not yet recruiting
- NCT07227909 — NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy · Phase 2 · not yet recruiting
- NCT07379684 — A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections · Phase 1 · recruiting
- NCT07526649 — Head Cooling in Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy (COOLHEAD-2b) · NA · not yet recruiting
Other University Children's Hospital, Zurich trials
Trials by the same sponsor.
- NCT06852313 — Save the Ovaries - Surgical Management of Simple Ovarian Cysts in Children and Adolescents · NA · recruiting
- NCT07368166 — Development of the PTSD-iMPACT to Measure PTSD-Related Functional Impairment in Children and Adolescents - A Validation · recruiting
- NCT06950047 — PediLoc® Blade Plate in Distal Femoral Osteotomies · completed
- NCT05971264 — Comparison of Bladder Pressure Versus Regional Intestinal Tissue Oxygenation in Infants · NA · recruiting
- NCT06045416 — Borrelia B-cell Diagnostics · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07415577 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Children's Hospital, Zurich
- Last refreshed: 4 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07415577.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing